Fixed-combination tablets of metformin and DPP-4 inhibitor teneligliptin for type 2 diabetes therapy. Formulated by API-integrated manufacturers, procured via tenders by public hospitals and chain pharmacies for supply to general practitioners and specialists in metabolic disorders.